Literature DB >> 8037210

Translocation involving 1p and 17q is a recurrent genetic alteration of human neuroblastoma cells.

L Savelyeva1, R Corvi, M Schwab.   

Abstract

Human neuroblastoma cells often are monosomic for the distal portion of 1p (1p36). We report that the deleted 1p material in cells of neuroblastoma lines is preferentially replaced by material from chromosome 17, resulting from an unbalanced 1;17 translocation. Chromosome 17 often acquires instability, followed by the integration of fragments into various marker chromosomes. As a consequence, 17q material can increase over 17p material. The nonrandom frequency of 1;17 translocations appears to indicate an as-yet-undefined contribution to neuroblastoma development.

Entities:  

Mesh:

Year:  1994        PMID: 8037210      PMCID: PMC1918368     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  18 in total

1.  Constitutional translocation t(1;17)(p36;q12-21) in a patient with neuroblastoma.

Authors:  G Laureys; F Speleman; G Opdenakker; Y Benoit; J Leroy
Journal:  Genes Chromosomes Cancer       Date:  1990-09       Impact factor: 5.006

2.  Deletion mapping of chromosomes 14q and 1p in human neuroblastoma.

Authors:  H Takayama; T Suzuki; H Mugishima; T Fujisawa; M Ookuni; M Schwab; M Gehring; Y Nakamura; T Sugimura; M Terada
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

3.  Definition of a continuous human cell line derived from neuroblastoma.

Authors:  J J Tumilowicz; W W Nichols; J J Cholon; A E Greene
Journal:  Cancer Res       Date:  1970-08       Impact factor: 12.701

4.  Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region.

Authors:  T Martinsson; A Weith; C Cziepluch; M Schwab
Journal:  Genes Chromosomes Cancer       Date:  1989-09       Impact factor: 5.006

5.  Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma.

Authors:  D N Shapiro; M B Valentine; S T Rowe; A E Sinclair; J E Sublett; W M Roberts; A T Look
Journal:  Am J Pathol       Date:  1993-05       Impact factor: 4.307

6.  Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system.

Authors:  H Ohgaki; R H Eibl; M Schwab; M B Reichel; L Mariani; M Gehring; I Petersen; T Höll; O D Wiestler; P Kleihues
Journal:  Mol Carcinog       Date:  1993       Impact factor: 4.784

7.  Absence of p53 gene mutations in primary neuroblastomas.

Authors:  K Vogan; M Bernstein; J M Leclerc; L Brisson; J Brossard; G M Brodeur; J Pelletier; P Gros
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  Molecular evaluation of abnormalities of the short arm of chromosome 1 in neuroblastoma.

Authors:  J D Hunt; A Tereba
Journal:  Genes Chromosomes Cancer       Date:  1990-07       Impact factor: 5.006

9.  Molecular analysis of chromosome 1 abnormalities in neuroblastoma.

Authors:  M K Ritke; R Shah; M Valentine; E C Douglass; A Tereba
Journal:  Cytogenet Cell Genet       Date:  1989

10.  There may be two tumor suppressor genes on chromosome arm 1p closely associated with biologically distinct subtypes of neuroblastoma.

Authors:  O Takeda; C Homma; N Maseki; M Sakurai; N Kanda; M Schwab; Y Nakamura; Y Kaneko
Journal:  Genes Chromosomes Cancer       Date:  1994-05       Impact factor: 5.006

View more
  12 in total

Review 1.  Patterns of oncogene activation in human neuroblastoma cells.

Authors:  R Corvi; L Savelyeva; M Schwab
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Search for neuroblastoma loci: characterization of tumor cell lines that could facilitate their positional cloning.

Authors:  M Romani; R Muresu; E V Volpi; C Rozzo; J M Marchi; I Casciano
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 3.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

Review 4.  Neuroblastoma tumour genetics: clinical and biological aspects.

Authors:  N Bown
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

5.  No mutations found by RET mutation scanning in sporadic and hereditary neuroblastoma.

Authors:  R M Hofstra; N C Cheng; C Hansen; R P Stulp; T Stelwagen; N Clausen; N Tommerup; H Caron; A Westerveld; R Versteeg; C H Buys
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

Review 6.  Neuroblastoma: current drug therapy recommendations as part of the total treatment approach.

Authors:  F Berthold; B Hero
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

7.  Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization.

Authors:  D Plantaz; G Mohapatra; K K Matthay; M Pellarin; R C Seeger; B G Feuerstein
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

8.  MYCN Amplification in Neuroblastoma: a Paradigm for the Clinical Use of an Oncogene.

Authors:  Manfred Schwab
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

9.  A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3.

Authors:  P S White; J M Maris; C Beltinger; E Sulman; H N Marshall; M Fujimori; B A Kaufman; J A Biegel; C Allen; C Hilliard; M B Valentine; A T Look; H Enomoto; S Sakiyama; G M Brodeur
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

10.  The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Authors:  Nadine Van Roy; Katleen De Preter; Jasmien Hoebeeck; Tom Van Maerken; Filip Pattyn; Pieter Mestdagh; Joëlle Vermeulen; Jo Vandesompele; Frank Speleman
Journal:  Genome Med       Date:  2009-07-27       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.